Health professional risk communication

Baxter Intravenous Solution Bags – Potential Leak During Spiking of Administration Port

Last updated

Summary

Product
0.4% Lidocaine & 5% Dextrose Injection, 0.9% Sodium Chloride Injection, USP, Lactated Ringer’s Injection, USP, and Metronidazole Injection, USP
Issue
Health products - Product quality
Health products - Product safety
What to do

See Key Messages below

Audience
Health professionals

Affected products

Product Name Package Size Product Code Market Authorization Holder DIN Lot Numbers/ Expiration Dates of products not recalled
0.4% Lidocaine & 5% Dextrose Injection 250 mL JB0972 Baxter Corporation 00828602 See Appendix A
0.9% Sodium Chloride Injection, USP 100 mL 250 mL JB1302 JB1322 Baxter Corporation 00060208 See Appendix A
Lactated Ringer’s Injection, USP 250 mL JB2322 Baxter Corporation 00061085 See Appendix A
Metronidazole Injection, USP 100 mL JB3415 Baxter Corporation 00870420 See Appendix A

Issue

Intravenous bags of Baxter’s 0.4% Lidocaine & 5% Dextrose Injection 250 mL, 0.9% Sodium Chloride Injection, USP 100 mL and 250 mL, Lactated Ringer’s Injection, USP 250 mL, and Metronidazole Injection, USP 100mL from certain lots have the potential to leak during the process of spiking the administration port.

The affected lots identified in Appendix A are not being recalled at this time in order to prevent a shortage of these medically necessary products.

 

Audience

Healthcare professionals including physicians, nurses, pharmacists, and other medical and support personnel including inventory management and home healthcare agencies involved in the administration and handling of the following Baxter products:

 

Key messages

  • Certain lots of Baxter intravenous solution bags have the potential to leak during the process of spiking the administration port.
  • Healthcare professionals are advised to:
    • NOT use the product if the defect is observed.
    • Follow guidance on the handling and verification of affected products (see the “Information for healthcare professionals” section) and
    • Ensure preparedness at points of use where affected products are identified.
  • Avoid using affected lots when feasible, particularly in situations requiring immediate product use (e.g., operating room, critical care and emergency). If only products from affected lots are available, additional measures should be considered, including the immediate supply of replacement bags at point of use and additional safety measures based on professional practice.

 

Background

There have been reports of leaks and/or disconnections observed during spiking on the administration port at the connection of the lower tubing section and the main port tube (see Appendix B as an example).

Baxter identified the cause of the leakage of these intravenous bags as a combination of factors related to the manufacturing process. Baxter has implemented appropriate measures to address the leaks and prevent reoccurrence. Products from the affected lots were distributed by Baxter Corporation in Canada beginning April 28, 2023.

The safety risks that could occur because of a leaking solution bag include:

  • Delay or interruption in therapy resulting in the administration of an inaccurate dose.
  • Healthcare professionals or patients being exposed to the drug product, including hazardous medications (e.g., cytotoxic chemotherapeutic drugs) when these medications have been added to the bags.
  • Patients receiving an infusion of contaminated solution due to microbial contamination of the solution at the point of use.
  • Healthcare professionals or patients being exposed to harm due to the solution leaking onto electrical equipment.

Baxter is taking a phased-in recall approach to prevent a product shortage. In consultation with Health Canada, the affected lots identified in Appendix A are not being recalled at this time to ensure the continued availability of these medically necessary products. Further market actions may be taken in the future once sufficient non affected supply is available.  

Baxter has previously initiated similar recalls of products affected by this issue, in consultation with Health Canada. For additional details, consult the Recalls and Safety Alerts Database on the Healthy Canadians Web Site.

 

Information for consumers (home patients)

Do NOT use the bags from affected lots if you see any damage or fluid leakage.

If you see any fluid leakage from the bags before or during treatment, stop using the product as there may be a potential risk of harm and consult your healthcare professional.

Gloves should be worn when handling the bag to avoid exposure to any cytotoxic drugs (such as some cancer drugs) that may have been added to the fluid in the bags.

Consult with your healthcare professional if you have used product from an affected lot, or are unsure and have questions or concerns about your health.

 

Information for healthcare professionals

  • Visually inspect the container. If the administration port is damaged, detached, or not present, discard container, as solution sterility may be compromised.
  • Check for administration port leaks after spiking the bag, by applying gentle pressure near the administration port. If leaks are found, discard solution as sterility may be compromised.
  • Due to the possibility that a port leak may not be immediately observed, wait 1-2 minutes before adding medications.
  • During the preparation of cytotoxic medications, follow pharmacy practice standards, and consider:
    • Spiking the bag first with either the administration set or the CSTD (closed system transfer device) bag spike
    • Inspect the bag prior to adding the medication
    • Admix the medication after spiking the bag
    • After adding the medication, leave the bag hanging under the hood for 1-2 extra minutes before sending to the units to ensure there is no leaking
    • Regularly monitor for leakage from the bag during treatment and discontinue use if leakage is observed.
    • Ensure spill kits are readily available on the unit when administering cytotoxic medications and staff are prepared, trained, and are aware of how to manage and handle hazardous materials
    • Gloves should be worn when handling the bags to avoid exposure to any hazardous medications that may have been added to the bags
  • Avoid using affected lots of Baxter IV solutions when feasible, particularly in situations requiring immediate product use (e.g., operating room, critical care and emergency). If only products from affected lots are available, additional measures should be considered, including the immediate supply of replacement bags at point of use and additional safety measures based on professional practice.

 

Action taken by Health Canada

Health Canada is communicating this important safety information to healthcare professionals and Canadians via the Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system.

Health Canada has requested Baxter Corporation, the market authorization holder for 0.4% Lidocaine & 5% Dextrose Injection, 250 mL, 0.9% Sodium Chloride Injection, USP 100 mL and 250 mL, Lactated Ringer’s Injection, USP 250 mL, and Metronidazole Injection, USP 100mL to ensure that they inform all affected healthcare professionals, patients and personnel administering or handling these products.

Health Canada is monitoring the company’s implementation of any additional corrective and preventative actions. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed.

 

Report health or safety concerns

Health Canada’s ability to monitor the safety of marketed health products depends on healthcare professionals and consumers reporting adverse reactions and medical device incidents. Any serious or unexpected adverse reactions in patients receiving 0.4% Lidocaine & 5% Dextrose Injection, 250 mL, 0.9% Sodium Chloride Injection, USP 100 mL and 250 mL, Lactated Ringer’s Injection, USP 250 mL, and Metronidazole Injection, USP 100mL should be reported to Baxter Corporation or to Health Canada.

Baxter Corporation

7125 Mississauga Rd.

Mississauga, ON

L5N 0C2

To correct your mailing address or fax number, contact Baxter Corporation at fca_canada@baxter.com

You can report any suspected adverse reactions associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, contact Health Canada at:

Health Product Compliance Directorate, Regulatory Operations and Enforcement Branch

E-mail: hpce-cpsal@hc-sc.gc.ca

Telephone: 1-800-267-9675

 

Original signed by

Brandon Gingrich

Senior Manager, Quality

Baxter Corporation – Canada

 

Appendix A: Affected Lots NOT Subject to Recall

Product Code Product Description                     Lot Number              Expiration Date          DIN

JB0972

(JB0972)
0.4% LIDOCAINE & 5%
DEXTROSE INJECTION (250ML)
W3E11C1 AUG 2024 00828602

JB2322

(JB2322P)
LACTATED RINGER'S
INJECTION, USP (250 ML)
W3F22C1 SEP 2024 00061085
JB3415 METRONIDAZOLE INJECTION,
500 mg / 100 mL, USP (100ML)
W3E30C1 NOV 2024 00870420

JB1302

(JB1302P)
0.9% SODIUM CHLORIDE
INJECTION, USP (100 ML)

W3D25C0

APR 2024

00060208
    W3D26C0 APR 2024  
    W3D29C2 APR 2024  
    W3E03C0 MAY 2024  
    W3E04C0 MAY 2024  
    W3E09C0 MAY 2024  
    W3E18C0 MAY 2024  
    W3E30C0 MAY 2024  
    W3F06C0 JUN 2024  
    W3F13C0 JUN 2024  
    W3F21C0 JUN 2024  
    W3F28C0 JUN 2024  
    W3F29C0 JUN 2024  
    W3G11C0 JUL 2024  
    W3G12C0 JUL 2024  
    W3G13C0 JUL 2024  
    W3G17C3 JUL 2024  
    W3G18C0 JUL 2024  

JB1322

(JB1322P)
0.9% SODIUM CHLORIDE
INJECTION, USP (250 ML)
W3D24B0 JUL 2024 00060208
    W3D27C0 JUL 2024  
    W3E01B0 AUG 2024  
    W3E02B0 AUG 2024  
    W3E05C1 AUG 2024  
    W3E10B0 AUG 2024  
    W3E13C1 AUG 2024  
    W3E15B1 AUG 2024  
    W3E16B0 AUG 2024  
    W3E25C2 AUG 2024  
    W3F01C0 SEP 2024  
    W3F01C0S SEP 2024  
    W3F02C1 SEP 2024  
    W3F05B0 SEP 2024  
    W3F12B0 SEP 2024  
    W3F14C0 SEP 2024  
    W3F16B0 SEP 2024  
    W3F19B0 SEP 2024  
    W3F20B0 SEP 2024  
    W3F21B0KX SEP 2024  
    W3F21B0X SEP 2024  
    W3F22C0 SEP 2024  
    W3F30C0 SEP 2024  
    W3G10B0 OCT 2024  
    W3G11B0 OCT 2024  
    W3G12B0K OCT 2024  
    W3G12B0X OCT 2024  
    W3G14C0 OCT 2024  
    W3G15C0 OCT 2024  
    W3G17B0 OCT 2024  
    W3G17B0S OCT 2024  
    W3G18B0 OCT 2024  
    W3G18B0S OCT 2024  

 

Appendix B

The following photo is an example of where the leaks can occur for the implicated lots:

Example bags of where the leaks can occur

 

Additional information

Details
Original published date:
Alert / recall type
Health professional risk communication
Category
Health products
Companies
Published by
Health Canada
Audience
Health professionals
Identification number
RA-74389

Get notified

Receive notifications for new and updated recalls and alerts by category.

Subscribe